ABT vs EW
Abbott Laboratories and Edwards Lifesciences, both Healthcare
Abbott Laboratories is the larger company at $154B against $50B. On trailing earnings ABT is the cheaper of the two at a P/E of 31.9 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +15% against -11% for ABT.
| Figure | ABT | EW |
|---|---|---|
| Last close | $114 | $90.77 |
| Market cap | $154B | $50B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 31.9 | 52.2 |
| Dividend yield | 2.1% | n/a |
| 1-year return | -11% | +15% |
| 5-year return | +3.2% | -19% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Abbott Laboratories
Revenue of $11B in Q1 2026, net income $1.1B. Its largest reported line is Nutritional Products, 41% of the disclosed total.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.